Population Health & Well-being Series

---

RSSWEBINARDHPAMA

Occurs monthly on the 3rd Tuesday starting on 10/20/2020 at 4:00 PM
Tuesday, October 20, 2020, 4:00 PM - 5:00 PM, Livestream Zoom

Globally, the healthcare landscape is rapidly evolving. Healthcare priorities are changing from curative care approaches to comprehensive, evidence-based integrative and preventive methods of disease and health management. Globally the major health challenges faced by populations include the epidemic of chronic noncommunicable diseases, the rising dilemma of mental health issues, inequity in women health outcomes, lack of access to basic health care in many communities, gaps in healthcare professionals’ education, and widening national and regional health disparities. The current COVID-19 pandemic has caused major societal and economic upheaval and at the same time exposed the cracks in our health systems. Additionally, a wide range of societal and environmental factors continue to negatively impact behaviors of individuals and their lifestyles. It is time for healthcare professionals to focus on the overarching goal of better and optimum health for all the world citizens and universal health coverage. Adopting a population health perspective, which utilizes multidisciplinary and intersectoral partnerships and optimizes on collaboration with the government/s, academia, public health institutions, research entities and relevant industries to achieve positive health outcomes would be a step in the right direction. Healthcare professionals must learn from each other to address health challenges at both local and global levels to achieve health for all ultimately leading to sustainable development of societies globally. This series will facilitate capacity building and lifelong learning among healthcare professionals, foster constructive discussion and exchange of ideas across intersectoral disciplines with a view to promote health resulting in positive population health outcomes.

1. 1) Discuss contemporary and critical topics relevant to healthcare, medicine and population health.
2. 2) Examine evidence-based practices germane to public health and patient care.
3. 3) Describe opportunities and challenges in the evolving face of healthcare and population health.

ACCME Accreditation Statement  The Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACCME Credit Designation Statement The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. DHP Accreditation Statement Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Department of Healthcare Professions (DHP) of the Ministry of Public Health. DHP Credit Designation Statement This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health’s Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 1.0 hour.

Disclosure of Relationships/Content Validity 

It is the policy of Weill Cornell Medicine-Qatar to adhere to Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias.

Scientific Planning Committee

Dr. Ravinder Mamtani, Dr. Sohaila Cheema, Dr. Mark Dimon Santos, Dr. Khalafalla Babikir, Dr. NandaKumar G. Pillai, Mr. Syed A Ansari M, Dr. Sunil Suresh Harikrishnan, Dr. Fatimah Isa, Dr. Amit Abraham, Dr. Karima Chaabna, Ms. Raji Anand, Ms. Yasmeen Kalverts, Ms. Samaah Chalil

• Have no relevant financial relationship to disclose. 
• Will not be discussing unlabeled/unapproved use of drugs or products.

Course Directors

Dr. Ravinder Mamtani & Dr. Sohaila Cheema

• Have no relevant financial relationship to disclose. 
• Will not be discussing unlabeled/unapproved use of drugs or products.

Course Faculty

Dr. Javaid Sheikh, Dr. Ravinder Mamtani, Dr. David Katz, Dr. William W. Pinsky, Ms. Paula M. Breen, Sheikh Dr. Mohamed A Thani, Dr. Adeel Butt, Dr. Sohaila Cheema, Dr. James Rippe, Dr. Hanan Abdul Rahim, Dr. Ashok Parchani, Dr. Suhaila Ghuloum, Dr. Rob Lawson, Dr. Pieter D'Hooghe, Dr. Albert Lowenfels, Dr. Penny Stern, Dr. Shagufta Feroz, Dr. Sheela Nambiar, Dr. Benjamin Kligler, Dr. Albert Lowenfels, Mr. Patrick Maisonneuve, Dr. Liz Arbittier:

• Have no relevant financial relationship to disclose. 
• Will not be discussing unlabeled/unapproved use of drugs or products.

Dr. Ronac Mamtani:

• Has disclosed the following relationships (a) Grants/Research Support Recipient-Merck and Company, Inc. (b) Consulting Fee-Astellas / Seattle genetics (c) Consulting Fee-Flatiron Health
• Will be discussing Immunotherapy (Pembrolizumab) and Flatiron national database

Dr. Rebecca Hubbard:

• Has disclosed the following relationships (a) Grants/Research Support Recipient-Merck and Company, Inc. (b) Grants/Research Support Recipient-Pfizer, Inc. (c) Grants/Research Support Recipient-Johnson and Johnson
• Will not be discussing unlabeled/unapproved use of drugs or products.

Dr. David Reilly:

• Has disclosed the following relationships (a) Ownership Interest-TheWELWorld.org
• Will not be discussing unlabeled/unapproved use of drugs or products.

Dr. Jyothi Pathak:

• Has disclosed the following relationships (a) Ownership Interest-Iris OB Health, Inc.
• Will not be discussing unlabeled/unapproved use of drugs or products.

Dr. Linda Gerber:

• Has disclosed the following relationships (a) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bisu, Inc
• Will not be discussing unlabeled/unapproved use of drugs or products.

Course Administrator

Yasmeen Kalverts:

• Has no relevant financial relationships to disclose.
• Will not be discussing unlabeled/unapproved use of drugs or products.

Independent Clinical Reviewer

Sohaila Cheema:

• Has no relevant financial relationships to disclose.
• Will not be discussing unlabeled/unapproved use of drugs or products.

---

The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.

---

Evaluation

An evaluation will be conducted online post activity. All participants are required to complete the Evaluation Form in order to qualify for a certificate. The evaluation allows us to assess the degree to which the activity met its objectives. It will also guide the planning of future activities and inform decisions about improving the educational program.

Registration Warning

Registration for courses managed by Weill Cornell Medicine-Qatar can only be completed through WCM-Q's official registration portal. Attendee registrations made through any other sites cannot be honored. WCM-Q is not able to refund fees paid through unaffiliated registration sites, such as eMedEvents.com, MedConfWorld.com, EventEgg.com, and 10times.com.

Please report any unauthorized websites or solicitations for registrations to [email protected].

Date	Empty Column	Title
		No activities are currently published for this month.
No upcoming dates have been setup.